Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
ZANDU REALTY ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ZANDU REALTY Mar-17 |
ADCOCK INGRAM Jun-14 |
ZANDU REALTY/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,670 | 321 | - | |
Low | Rs | 1,030 | 232 | - | |
Sales per share (Unadj.) | Rs | 63.3 | 95.5 | - | |
Earnings per share (Unadj.) | Rs | 63.9 | -24.1 | - | |
Cash flow per share (Unadj.) | Rs | 63.9 | -20.0 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 2,438.1 | 75.0 | - | |
Shares outstanding (eoy) | m | 0.81 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 21.2 | 2.9 | 733.9% | |
Avg P/E ratio | x | 21.0 | -11.5 | -183.1% | |
P/CF ratio (eoy) | x | 21.0 | -13.9 | -151.8% | |
Price / Book Value ratio | x | 0.6 | 3.7 | 15.0% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 1,089 | 46,656 | 2.3% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 3 | 2,928 | 0.1% | |
Avg. sales/employee | Rs Th | 0 | 3,756.2 | - | |
Avg. wages/employee | Rs Th | 0 | 682.1 | - | |
Avg. net profit/employee | Rs Th | 0 | -946.5 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 51 | 16,125 | 0.3% | |
Other income | Rs m | 117 | 113 | 103.4% | |
Total revenues | Rs m | 168 | 16,238 | 1.0% | |
Gross profit | Rs m | -37 | -2,794 | 1.3% | |
Depreciation | Rs m | 0 | 696 | 0.0% | |
Interest | Rs m | 14 | 437 | 3.3% | |
Profit before tax | Rs m | 65 | -3,814 | -1.7% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 14 | 238 | 5.7% | |
Profit after tax | Rs m | 52 | -4,063 | -1.3% | |
Gross profit margin | % | -72.6 | -17.3 | 419.0% | |
Effective tax rate | % | 20.8 | -6.2 | -332.5% | |
Net profit margin | % | 101.0 | -25.2 | -400.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 270 | 11,810 | 2.3% | |
Current liabilities | Rs m | 118 | 6,645 | 1.8% | |
Net working cap to sales | % | 295.9 | 32.0 | 923.7% | |
Current ratio | x | 2.3 | 1.8 | 128.7% | |
Inventory Days | Days | 12,983 | 111 | 11,706.7% | |
Debtors Days | Days | 0 | 124 | 0.0% | |
Net fixed assets | Rs m | 1,824 | 6,884 | 26.5% | |
Share capital | Rs m | 81 | 75 | 107.7% | |
Net worth | Rs m | 1,975 | 12,657 | 15.6% | |
Long term debt | Rs m | 0 | 4,448 | 0.0% | |
Total assets | Rs m | 2,093 | 23,909 | 8.8% | |
Interest coverage | x | 5.6 | -7.7 | -72.3% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0 | 0.7 | 3.6% | |
Return on assets | % | 3.2 | -15.2 | -20.8% | |
Return on equity | % | 2.6 | -32.1 | -8.2% | |
Return on capital | % | 4.0 | -19.8 | -20.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 59 | 1,376 | 4.3% | |
From Investments | Rs m | -160 | -423 | 37.8% | |
From Financial Activity | Rs m | 101 | 4,037 | 2.5% | |
Net Cashflow | Rs m | 0 | 4,990 | 0.0% |
Compare ZANDU REALTY With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare ZANDU REALTY With: JUBILANT PHARMOVA DENIS CHEM LAB ANUH PHARMA GLAND PHARMA MESCO PHARMA
Indian share markets continued the momentum as the session progressed and ended on firm footing.